Prosecution Insights
Last updated: April 19, 2026
Application No. 17/943,036

INJECTION DEPTH INDICATION VIA INJECTION NEEDLE ILLUMINATION

Final Rejection §103
Filed
Sep 12, 2022
Examiner
SCHMIDT, EMILY LOUISE
Art Unit
3783
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Welch Allyn Inc.
OA Round
2 (Final)
59%
Grant Probability
Moderate
3-4
OA Rounds
3y 5m
To Grant
95%
With Interview

Examiner Intelligence

Grants 59% of resolved cases
59%
Career Allow Rate
581 granted / 992 resolved
-11.4% vs TC avg
Strong +36% interview lift
Without
With
+36.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
77 currently pending
Career history
1069
Total Applications
across all art units

Statute-Specific Performance

§101
0.6%
-39.4% vs TC avg
§103
48.9%
+8.9% vs TC avg
§102
25.8%
-14.2% vs TC avg
§112
18.7%
-21.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 992 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1-6, 8, and 9 is/are rejected under 35 U.S.C. 103 as being unpatentable over DeVega (US 2011/0196312 A1) in view of Kahook (US 2018/0168863 A1), Perez (US 2011/0015575 A1), Green Jr. (US 2005/0080384 A1), and Berkman et al. (US 10,195,347 B1). With regard to claims 1, 2, and 6, DeVega teaches a medical device, comprising: a head having a base (Fig. 3a member 330); a tube having a proximal end, a distal end, a first central channel extending from the proximal end to distal end, and a longitudinal axis extending substantially centrally through the first central channel (Fig. 3a member 310); a plunger slidably disposed at least partly within the first central channel of the tube (Fig. 3a member 350), the plunger defining a second central channel, and the longitudinal axis extending substantially centrally through the second central channel (Figs. 3a and 3b, channel within 340 where 348/349 are located); a cap removably attached to a distal end of the plunger (Fig. 3b, member 360 capable of being removed); and an optic assembly having a light source being disposed at least partly within the second central channel (Fig. 3b light 346) and being configured to: direct the radiation through the cap at the distal end of the plunger (Fig. 3a and 3b, light is directed through 360 which would then be directed to the distal end to illuminate the target). In the embodiment of Figs. 3 DeVega does not disclose a piercing member or that the base is removably attachable to the tube. However, in Figs. 1 DeVega shows a needle may be used (Fig. 1a needle 132). Further, Kahook teaches a syringe for treatment which also directs light in which the needle is connectable to the syringe via known fastening means such as a luer or threads ([0049], [0066], [0077], Fig. 1 cannula 14 is attached via a known fastening mechanism). It would have been obvious to a person having ordinary skill in the art before the effective filing date of the claimed invention to removably attach a piercing member in the embodiment of Figs. 3 of DeVega as DeVega teaches needles are effective for delivery and Kahook teaches removable fastening means are known in the art and would yield the same predictable result of delivering fluid from the syringe. Additionally, it has been held that combining two embodiments disclosed adjacent to each other in a prior art patent does not require a leap of inventiveness and involves only routine skill in the art, Boston Scientific v. Cordis Fed. Cir. 2009. This provides a fluid tight seal between the base and the tube which are fluidly connected for delivery. DeVega teaches a light source is provided within the plunger to illuminate the target but do not specifically disclose the optic assembly includes both alight source and a light pipe. However, Perez teaches a light guide which comprises a tube (a light pipe tube) which houses fiber optic strands (a light pipe of conductive material) to transmit light from an LED light source which is beneficial in that the fiber optic bundles do not emit heat and the lighting arrangement may include a lens to disperse light as needed ([0023]-[0025]). It would have been obvious to a person having ordinary skill in the art before the effective filing date of the claimed invention to use a light pipe through a light tube to direct LED light in DeVega as Perez teaches such is effective for controlling the light delivered to the treatment area without generating heat and would still yield the same predictable result of illumination. DeVega does not disclose that a portion of the light pipe is encased within the cap. However, Green Jr. teaches a syringe with a light source route through the plunger and states that the LED is attached to the seal ([0017]) and that the distal end is formed by the seal and light emitting diode ([0036]), however, the Figures are poor quality. Further, Berkman et al. teach an LED installed within a cavity of the plunger seal (Figs. 1-3, LED 124, cavity 114, Col. 3 lines 51-52). It would have been obvious to a person having ordinary skill in the art before the effective filing date of the claimed invention to place a portion of the light pipe within the cap of DeVega as Green Jr. teach a similar syringe for directing light through a clear seal with the light attached to the seal and Berkman et al. show how a light may be within a cavity of the seal. Placing the light within the seal as opposed to just outside the seal yields the same result as light is still directed in the same direction through the seal for the same purpose. Additionally, Applicant has not disclosed that such an arrangement provides an advantage, is used for a particular purpose, or solves a stated problem. One of ordinary skill in the art, furthermore, would have expected the Applicant's invention to perform equally well with the light and cap of DeVega as light is still provided in the same manner. With regard to claim 3, DeVega teaches a light source may be an LED ([0023]) and as combined an LED would provide light to the light guide as such is a known light source. Perez also teaches the use of LEDs. With regard to claims 4 and 5, the area at the proximal end 370 (Fig. 3b) is taken as the housing as it houses the electrical source, DeVega teaches circuitry and a power source are provided for the light source ([0023]) which as combined would be located proximally to direct light through the light pipe. DeVega teaches the LEDS may be programmable ([0023]). It would have been obvious to a person having ordinary skill in the art at the time the invention was made to include a processor in DeVega as this would be needed to carry out programming of the LEDs. With regard to claim 8, see Fig. 3b member 360 is considered as the cap and is translucent ([0022]) and light is directed through the lumen, cap, barrel, and outlet to illuminate the target area. DeVega does not explicitly show how the cap is attached to the plunger. However, there are a limited number of options for construction, either the cap has a channel around the plunger or has an end face attached to the plunger. Additionally, either the lumen of the plunger connects to the cap or does not. It would have been obvious to a person having ordinary skill in the art at the time the invention was made to have a channel of the cap connect to a channel of the plunger in DeVega as there are a limited number of options for construction for one of ordinary skill which would yield the same predictable result of the cap connected to the plunger for directing light. Further, it would be obvious to have an open connection between the plunger and cap as this would be beneficial as it would better direct light by removing a barrier to light transmission. With regard to claim 9, DeVega teaches circuitry, a switch, and a power source are provided for the light source ([0020], [0023]). Claim(s) 7 and 10 is/are rejected under 35 U.S.C. 103 as being unpatentable over DeVega (US 2011/0196312 A1), Kahook (US 2018/0168863 A1), Perez (US 2011/0015575 A1), Green Jr. (US 2005/0080384 A1), and Berkman et al. (US 10,195,347 B1) as applied to claim 1 above, and further in view of Cowan et al. (US 2017/0290993 A1). With regard to claims 7 and 10, DeVega teaches a device substantially as claimed. Perez teaches the material of the light pipe as noted above. DeVega does not disclose a sleeve. However, Cowan et al. teach a shield may be provided around the barrel of a syringe through which light is transmitted to increase the transmission of light through the barrel ([0111]). Cowan et al. teach depending on light transmission portions may be translucent and other portions opaque. It would have been obvious to a person having ordinary skill in the art before the effective filing date of the claimed invention to use a shield in DeVega as Cowan et al. teach this is beneficial for controlling the transmission of light and to have such a shield be moveable so portions may be opaque or translucent as desired as Cowan et al. teach various arrangements may be desired based on desired transmission. Response to Arguments Applicant’s arguments with respect to the claim(s) have been considered but are moot because the new ground of rejection does not rely on any reference applied in the prior rejection of record for any teaching or matter specifically challenged in the argument. The previous objections are withdrawn in light of the amendments. The Examiner maintains that member 360 of DeVega provides a cap which would be capable of being removed. There is no specific structure recited for connection of the cap. It is not clear regarding claim 7, how the addition of the limitation to light exiting the outer surface of the tube would distinguish over the references. In DeVega, as combined with Cowan et al., light would exit the tube based on the placement of the shield of Cowan et al. Regarding claim 10, the obviousness rejection includes motivation as to why the tube would be slidable and it would slidably movable to a location as recited. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to EMILY L SCHMIDT whose telephone number is (571)270-3648. The examiner can normally be reached Monday through Thursday 7:00 AM to 4:30 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kevin Sirmons can be reached at 571-272-4965. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /EMILY L SCHMIDT/Primary Examiner, Art Unit 3783
Read full office action

Prosecution Timeline

Sep 12, 2022
Application Filed
Oct 31, 2025
Non-Final Rejection — §103
Feb 04, 2026
Response Filed
Feb 23, 2026
Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599750
VASCULAR ACCESS CONNECTOR SUPPORT DEVICE, SYSTEMS, AND METHODS
2y 5m to grant Granted Apr 14, 2026
Patent 12576214
BUTTON AND BUTTON ASSEMBLY FOR A DRUG DELIVERY DEVICE
2y 5m to grant Granted Mar 17, 2026
Patent 12569625
RIGID NEEDLE SHIELD REMOVER WITH DROP TEST FEATURE FOR AUTOINJECTOR
2y 5m to grant Granted Mar 10, 2026
Patent 12544516
Ultra-Low Waste Disposable Syringe with Self-Adjusting Integrated Safety Features
2y 5m to grant Granted Feb 10, 2026
Patent 12502482
COLLAR CAM LOCK FOR INJECTION DEVICES
2y 5m to grant Granted Dec 23, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
59%
Grant Probability
95%
With Interview (+36.0%)
3y 5m
Median Time to Grant
Moderate
PTA Risk
Based on 992 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month